Form 4: 10x Genomics Insider Sells Shares for Tax Obligations

Benjamin J. Hindson, President and Chief Scientific Officer of 10x Genomics, sold 7,486 shares of Class A Common Stock to cover tax withholding obligations.

Summary

• Benjamin J. Hindson, President and Chief Scientific Officer of 10x Genomics, Inc. (TXG), reported a sale of company stock.
• The transaction involved 7,486 shares of Class A Common Stock.
• The shares were sold at a price of $13.787 per share.
• The sale occurred on August 22, 2025.
• Following this transaction, Mr. Hindson beneficially owns 440,888 shares of Class A Common Stock.
• The sale was executed to cover tax withholding obligations related to the vesting of restricted stock units.

Sentiment

Score: 6

Explanation: The transaction is a routine, non-discretionary sale to cover tax obligations, which is a neutral event. The use of a 10b5-1 plan adds a slight positive as it indicates pre-planning and adherence to best practices, preventing negative interpretations of insider selling.

Positives

• The sale was non-discretionary, specifically to cover tax withholding obligations, which is a common and expected event for executives receiving equity compensation.
• The transaction was made pursuant to a Rule 10b5-1(c) plan, indicating a pre-arranged sale not based on new insider information.

Negatives

• A reduction in direct insider ownership by 7,486 shares, although for a specific, non-discretionary reason.

Future Outlook

This Form 4 filing does not contain any forward-looking statements or guidance regarding the company's future performance or strategic direction.

Management Comments

• The shares were sold to cover tax withholding obligations in connection with the vesting of restricted stock units.

Industry Context

Insider transactions, particularly those related to tax withholding from equity compensation, are routine occurrences across all industries for publicly traded companies. This filing reflects a standard practice for executives managing their equity awards.

Comparison to Industry Standards

• The sale of shares to cover tax withholding obligations upon the vesting of restricted stock units is a standard and common practice for executives in public companies across various sectors, including biotechnology and life sciences, such as Illumina (ILMN) or Pacific Biosciences (PACB).
• The use of a Rule 10b5-1(c) plan for such transactions is also a widely adopted best practice to mitigate concerns about insider trading, demonstrating adherence to corporate governance standards.

Corporate Governance

Stakeholder Impact

• Shareholders: A minor reduction in direct insider ownership, but the reason (tax withholding) is common and generally not interpreted negatively. The use of a 10b5-1 plan provides transparency.

Key Dates

Recommendation

This Form 4 reports a routine, non-discretionary sale of shares by an executive to cover tax withholding obligations upon the vesting of restricted stock units. Such transactions are common and generally do not reflect a change in management's outlook or confidence in the company's future. Therefore, this filing alone does not provide a basis for a 'buy' or 'sell' recommendation, warranting a 'hold' position based solely on this specific disclosure.

Keywords

10x Genomics, TXG, Insider Trading, Form 4, Stock Sale, Benjamin J. Hindson, Tax Withholding, Restricted Stock Units, Equity Compensation, Officer Transaction